Thelansis

Congenital Heart Block Market Outlook Thelansis’s “Congenital Heart Block Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Heart Block treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajector...

Congenital Heart Block Market Outlook Thelansis’s “Congenital Heart Block Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Heart Block treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Congenital Heart Block Overview Congenital heart block or atrioventricular block is a loss in the normal function of the cardiac electroconductive pathways that connect the sinoatrial node (SA node) to the ventricles via conduction through the atrioventricular node (AV node). The congenital heart block associated with neonatal lupus is considered a form of passively acquired autoimmune disease in which maternal autoantibodies to the intr...

  Congenital heart block or atrioventricular block is a loss in the normal function of the cardiac electroconductive pathways that connect the sinoatrial node (SA node) to the ventricles via conduction through the atrioventricular node (AV node). The congenital heart block associated with neonatal lupus is considered a form of passively acquired autoimmune disease in which maternal autoantibodies to the intracellular ribonucleoproteins Ro (SS-A) and La (SS-B) cross the placenta and injure the previously normal fetal heart. Women with serum titers of anti-Ro antibody carry a 3% risk of having a child with neonatal lupus syndrome. Recurrence rates are about 18%. Chronic idiopathic fibrosis and sclerosis of the conduction system in Lenegre's disease cause half of the cases. Another common cause is ischemic heart disease, responsible for 40% of cases. It is associated with hypertrophic obstructive cardiomyopathy and infiltrative diseases like sarcoidosis and amyloidosis. First-degree c...

  Congenital heart block or atrioventricular block is a loss in the normal function of the cardiac electroconductive pathways that connect the sinoatrial node (SA node) to the ventricles via conduction through the atrioventricular node (AV node). The congenital heart block associated with neonatal lupus is a form of passively acquired autoimmune disease in which maternal autoantibodies to the intracellular ribonucleoproteins Ro (SS-A) and La (SS-B) cross the placenta and injure the previously normal fetal heart. Women with serum titers of anti-Ro antibody carry a 3% risk of having a child with neonatal lupus syndrome. Recurrence rates are about 18%. Chronic idiopathic fibrosis and sclerosis of the conduction system in Lenegre's disease cause half of the cases. Another common cause is ischemic heart disease, responsible for 40% of cases. It is associated with hypertrophic obstructive cardiomyopathy and infiltrative diseases like sarcoidosis and amyloidosis. First-degree congenital b...